• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
CARA

CARA

Cara Therapeutics, Inc.

NASDAQHealthcareBiotechnologyUS

USD5.32

-0.14 (-2.56%)

Company Profile

CEO

Christopher A. Posner

IPO Date

2014-01-31

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$4.80

Prev. Close

$5.46

Day Low

$5.28

Day High

$5.52

52W Low

$5.28

52W High

$31.32

Market Cap

$0.01B

Volume

0.24M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

72.7%

Avg Negative

1.9%

Avg Neutral

25.4%

News Feed

Why Cara Therapeutics Shot Higher Today

The Motley Fool·8/24/2021·↑ positive

CARA Stock: The Huge FDA News Sending Cara Therapeutics Skyrocketing Today

InvestorPlace·8/24/2021·↑ positive

Biotech Stock Takes on Technical Ceiling After FDA Okay

Schaeffers Research·8/24/2021·↑ positive

Why Is Cara Therapeutics Stock Trading Higher Today?

Benzinga·8/24/2021·↑ positive

See Why Cara Therapeutics (CARA) Stock Is Moving Higher On Tuesday

Benzinga·8/24/2021·↑ positive

Cara Therapeutics Shares Increase Over 20% Pre-Market: Why It Happened

Pulse2·8/24/2021·↑ positive

Vifor Pharma and Cara Therapeutics announce U.S. FDA approval of KORSUVA™ injection for the treatment of moderate-to-severe pruritus in hemodialysis patients

Business Wire·8/24/2021·↑ positive

Cara Therapeutics and Vifor Pharma announce U.S. FDA approval of KORSUVA™ (difelikefalin) injection for the treatment of moderate-to-severe pruritus in hemodialysis patients

GlobeNewsWire·8/23/2021·↑ positive

Is the Options Market Predicting a Spike in Cara Therapeutics (CARA) Stock?

Zacks Investment Research·8/11/2021·↓ negative

Cara Therapeutics: 200% Upside Possible With FDA Approval

Seeking Alpha·8/11/2021·↑ positive